- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Tyra Biosciences: Piper Sandler erhöht Kursziel wegen Wachstumsaussichten auf 42 US-Dollar | 1 | Investing.com Deutsch | ||
| Fr | Piper Sandler raises Tyra Biosciences stock price target to $42 on growth outlook | 2 | Investing.com | ||
| 16.12.25 | Wedbush raises Tyra Biosciences stock price target to $37 on pipeline potential | 1 | Investing.com | ||
| TYRA BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 04.12.25 | Goldman Sachs initiates coverage of Tyra Biosciences stock with Early-Stage Biotech rating | 1 | Investing.com | ||
| 01.12.25 | Tyra Biosciences appoints two key executives to leadership team | 1 | Investing.com | ||
| 01.12.25 | Tyra Biosciences Strengthens Leadership Team with Appointments of Bhavesh Ashar as Chief Operating Officer and Heather Faulds as Chief Regulatory Officer | 135 | PR Newswire | CARLSBAD, Calif., Dec. 1, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation... ► Artikel lesen | |
| 01.12.25 | Tyra Biosciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 06.11.25 | Tyra Biosciences GAAP EPS of -$0.50 beats by $0.05 | 1 | Seeking Alpha | ||
| 05.11.25 | Tyra Biosciences Reports Third Quarter 2025 Financial Results and Highlights | 103 | PR Newswire | - Dosed first patients with dabogratinib in BEACH301 and SURF302; interim results from both studies expected in 2026 -
- Expanded development of dabogratinib... ► Artikel lesen | |
| 10.09.25 | Oppenheimer raises Tyra Biosciences stock price target to $36 on market potential | 3 | Investing.com | ||
| 22.08.25 | Tyra Biosciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 21.08.25 | Achondroplasie-Studie: Tyra Biosciences behandelt erstes Kind mit Dabogratinib | 4 | Investing.com Deutsch | ||
| 21.08.25 | Tyra Biosciences doses first child in achondroplasia treatment trial | 1 | Investing.com | ||
| 21.08.25 | Tyra Biosciences Announces First Child Dosed in BEACH301, its Phase 2 Study for Dabogratinib (TYRA-300) in Pediatric Achondroplasia | 225 | PR Newswire | -Dabogratinib is the only oral FGFR3-selective inhibitor in clinical development for achondroplasia-
-Initial results from safety sentinel cohort expected in 2H... ► Artikel lesen | |
| 14.08.25 | Tyra Biosciences, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 14.08.25 | Tyra Biosciences Reports Second Quarter 2025 Financial Results and Highlights | 673 | PR Newswire | - Dosed first patient in SURF302 for intermediate risk non-muscle invasive bladder cancer (IR NMIBC) -
- Cash, cash equivalents, and marketable securities of $296.3... ► Artikel lesen | |
| 30.06.25 | Tyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302) | 348 | PR Newswire | -TYRA-300 is the only orally administered investigational agent in clinical development for IR NMIBC-
-Initial 3-month complete response (CR) data expected to be... ► Artikel lesen | |
| 08.05.25 | Tyra Biosciences Reports First Quarter 2025 Financial Results and Highlights | 460 | PR Newswire | - BEACH301 study of TYRA-300 for Pediatric Achondroplasia (ACH) Open for Enrollment -
- Initiated patient dosing in SURF431 study of TYRA-430 for hepatocellular... ► Artikel lesen | |
| 27.03.25 | Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights | 377 | PR Newswire | - Three INDs cleared by US FDA for TYRA's proprietary precision small molecules -
- TYRA-300 to be evaluated in three Phase 2 studies: SURF302 for Intermediate Risk... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CG ONCOLOGY | 53,81 | -3,67 % | What Analysts Are Saying About CG Oncology Stock | ||
| QIAGEN | 46,130 | +0,01 % | AKTIE IM FOKUS: Qiagen schnellen zum Handelsschluss hoch - Strategische Optionen | FRANKFURT (dpa-AFX) - Die Papiere von Qiagen sind zum Börsenschluss am Dienstag nach oben geschnellt. Mit der Schlussauktion auf Xetra stiegen sie um 12,4 Prozent auf 44,11 Euro und waren damit im... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 70,02 | -12,32 % | Apogee Therapeutics: Empfehlung liefert +129% in 6 Monaten | Im Juli letzten Jahres präsentierten wir im Rahmen unserer Berichterstattung und innerhalb unserer erfolgreichen Community die Aktie von Apogee Therapeutics als heißen Kauftipp. Grundlage war eine ausgeprägte... ► Artikel lesen | |
| COGENT BIOSCIENCES | 36,680 | -7,19 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio | New Drug Application (NDA) for NonAdvSM submitted in December 2025, NDA submission for AdvSM on track for 1H 2026NDA submission for GIST on track for April 2026; bezuclastinib has the potential to... ► Artikel lesen | |
| IMMUNOME | 25,870 | +0,15 % | Immunome: Guggenheim bestätigt Kaufempfehlung nach 400-Millionen-Dollar-Finanzierung | ||
| SUMMIT THERAPEUTICS | 16,490 | -5,07 % | Summit Therapeutics to Present at Upcoming Investor Conferences | Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that it will participate in and present at four upcoming investor conferences during the remainder of this... ► Artikel lesen | |
| BEAM THERAPEUTICS | 31,560 | -7,91 % | Bernstein raises Beam Therapeutics stock price target to $41 on FDA pathway | ||
| BIONTECH | 98,10 | -0,05 % | Milliardenhoffnung: BioNTech greift mit Krebsforschung neu an: Goldman Sachs löst Kursschub mit optimistischem Onkologie-Ausblick aus | Die US-Investmentbank Goldman Sachs hat die Aktie von BioNTech deutlich hochgestuft. Statt auf das abklingende Impfstoffgeschäft konzentriert sich die Bewertung nun auf die wachstumsstarke Pipeline... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 311,12 | +2,02 % | Piper Sandler bekräftigt "Overweight"-Rating für Praxis Precision Medicines | ||
| ALUMIS | 24,520 | -6,70 % | Chardan Capital initiates coverage on Alumis stock with Buy rating | ||
| VERA THERAPEUTICS | 47,490 | -2,58 % | Cantor Fitzgerald reiterates Overweight rating on Vera Therapeutics stock | ||
| RECURSION PHARMACEUTICALS | 4,730 | -4,64 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen | |
| NUVALENT | 106,44 | -4,96 % | Royalty Pharma plc: Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million | NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a pre-existing royalty interest in Nuvalent's neladalkib and zidesamtinib from an... ► Artikel lesen | |
| VENTYX BIOSCIENCES | 14,030 | +0,83 % | Ventyx Biosciences, Inc. - 8-K, Current Report | ||
| IMMUNOVANT | 26,010 | -0,65 % | Immunovant Inc.: Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients | First-ever potentially disease-modifying therapy for uncontrolled Graves' disease patientsOf 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response... ► Artikel lesen |
Das Unternehmen TYRA BIOSCIENCES INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -1,75 % bei einem Aktienkurs von 30,370 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TYRA BIOSCIENCES INC finden Sie auf Wallstreet Online.